Rafael (NYSE:RFL) versus CaliberCos (NASDAQ:CWD) Financial Comparison

Rafael (NYSE:RFL) and CaliberCos (NASDAQ:CWD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Rafael and CaliberCos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	0	0	0	0	N/A
CaliberCos	0	0	0	0	N/A

Profitability

This table compares Rafael and CaliberCos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rafael	-5,329.44%	-36.57%	-34.92%
CaliberCos	-19.84%	-17.74%	-5.61%

Risk & Volatility

Rafael has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, CaliberCos has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Insider and Institutional Ownership

11.3% of Rafael shares are owned by institutional investors. Comparatively, 4.1% of CaliberCos shares are owned by institutional investors. 9.7% of Rafael shares are owned by company insiders. Comparatively, 42.3% of CaliberCos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Rafael and CaliberCos”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$540,000.00	83.25	-$1.88 million	($1.20)	-1.53
CaliberCos	$90.94 million	0.16	-$12.70 million	($0.67)	-0.99

Rafael has higher earnings, but lower revenue than CaliberCos. Rafael is trading at a lower price-to-earnings ratio than CaliberCos, indicating that it is currently the more affordable of the two stocks.

Summary

CaliberCos beats Rafael on 7 of the 11 factors compared between the two stocks.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

About CaliberCos

Caliber (NASDAQ: CWD) is a vertically integrated alternative asset management firm whose purpose is to build generational wealth for investors seeking to access opportunities in middle-market assets. Caliber differentiates itself by creating, managing, and servicing proprietary products, including middle-market investment funds, private syndications, and direct investments which are managed by our in-house asset services group. Our funds include investment vehicles focused primarily on real estate, private equity, and debt facilities. Additional information can be found at Caliberco.com and CaliberFunds.co.